West Pharmaceutical Services, Inc. (WST)

NYSE · Health Care · market cap 22.81B

Share price

$366.60

At the last nightly close

Intrinsic value

$156.09

Range $136.92 – $185.42 — the conservative figure is the low end.

Margin of safety

-57.4%

($156.09 − $366.60) ÷ $366.60

EV / EBIT

109.0

On the median operating profit of 15 fiscal years through 2025.

How these numbers are computed

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.

The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-09-03.

Key metrics

Price / earnings46.9
Price / book8.6
EV / EBITDA27.8
FCF / EV+0.7%
Return on equity+19.1%
Return on assets+11.4%
Debt / equity0.11
Gross margin+36.8%

Market position

52-week high$366.60
52-week low$230.63
From 52-week high0.0%
RSI (14)66.6
200-day moving average$309.93

Annual financials

PeriodRevenueOperating incomeNet incomeEPSFree cash flow
2025-FY3.07B636.1M493.7M6.83468.9M
2024-FY2.89B590.9M492.7M6.75276.4M
2023-FY2.95B707.4M593.4M7.98414.5M
2022-FY2.89B760.8M585.9M7.87439.4M
2021-FY2.83B752.3M661.8M8.67330.6M

Filed figures from SEC EDGAR, in the reporting currency.

Next earnings

Q4 2026 expectedOctober 22, 2026
Consensus EPS estimate2.19

Recent news

The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on WST.

Run the board on WST

10 free analyses · no signup, no card

This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.